Inceptor Bio doses first subject in trial of IB-T101 for renal cell carcinoma
snippet
US-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead programme, IB-T101, for clear cell renal cell carcinoma (ccRCC).
Source
Clinical Trials Arena